Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

labois4u 6 posts  |  Last Activity: Feb 11, 2016 7:43 AM Member since: Jun 28, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • labois4u labois4u Feb 11, 2016 7:43 AM Flag

    These patents and their non-
    extended expiration dates are:

    U.S. Patent No. 7,544,369 (expires June 6, 2025),

    U.S. Patent No. 7,718,189 (expires June 6, 2025),

    U.S. Patent No. 8,226,975 (expires August 15, 2028)
    ,

    U.S. Patent No. 8,632,804 (expires December 5, 2026
    ),

    U.S. Patent No. 8,802,137 (expires October 29, 2023
    ),

    U.S. Patent No. 8,679,532 (expires December 5, 2026
    ),

    U.S. Patent No. 8,642,075 (expires December 5, 2026
    ), and

    U.S. Patent No. 8,673,348 (expires December 5, 2026
    ).
    We also own U.S. Patent No. 8,673,349
    (expires December 5, 2026), which covers methods f
    or treating a
    Burkholderia
    infection in a
    patient comprising administering to the patient an
    aerosolized composition comprising ARIKAYCE. In add
    ition to our nine issued patents that
    cover ARIKAYCE composition and its use in treating
    lung infections, we own twelve pending U.S. patent
    applications that cover the
    ARIKAYCE composition, methods of using ARIKAYCE and
    methods for making ARIKAYCE.
    Two patents have been granted by the
    European Patent Office ("EPO") (European Patent Nos
    . 1581236 and 1909759) and one
    additional patent application (Application No. 1115
    9754.8) has been allowed. Currently, our European P
    atent No. 1909759 is being opposed by
    a third party. In addition, we have six application
    s pending before the EPO. Thirty nine patents have
    also issued in major foreign markets,
    e.g., Japan, China, Korea, Australia, and India, wh
    ich cover ARIKAYCE and methods of using ARIKAYCE fo
    r treating lung infections. Forty
    five foreign patent applications are pending that c
    over the ARIKAYCE composition and its use in treati
    ng lung infections, including
    Pseudomonas
    and NTM. We anticipate that in the U.S., we will ha
    ve potential patent coverage for ARIKAYCE and its u
    se in treating lung
    infections, including
    Pseudomonas
    and NTM, through at least February 2029, which incl
    udes an additional six months of pe

    Sentiment: Strong Buy

  • Reply to

    Piper Jaffray confident INSM will double value!

    by fcc_wi Jan 12, 2016 11:37 AM
    labois4u labois4u Jan 12, 2016 1:44 PM Flag

    PJ is wrong!... By the end of 2016 above $100!!

    Sentiment: Strong Buy

  • Reply to

    We Stay On Track!...Mr.Lewis

    by labois4u Dec 2, 2015 5:05 AM
    labois4u labois4u Dec 4, 2015 8:53 AM Flag

    On track!

    Sentiment: Strong Buy

  • Reply to

    We Stay On Track!...Mr.Lewis

    by labois4u Dec 2, 2015 5:05 AM
    labois4u labois4u Dec 3, 2015 1:41 PM Flag

    liar!

    Sentiment: Strong Buy

  • Reply to

    We Stay On Track!...Mr.Lewis

    by labois4u Dec 2, 2015 5:05 AM
    labois4u labois4u Dec 3, 2015 9:59 AM Flag

    Still on track!

    Sentiment: Strong Buy

  • we remain on track with our regulatory process in Europe. We are finalizing our responses to the EMA's 120-day questions, and we still expect to submit these by the end of this year. This timing support a potential EMA opinion around the middle of 2016. We will update you again once the EMA provides us with their final assessment on the potential for approval of ARIKAYCE.

    Sentiment: Strong Buy

INSM
13.06+0.27(+2.11%)Feb 12 4:00 PMEST